Ask AI
ProCE Banner Activity

DESTINY-Breast05: Interim Analysis of a Phase III Trial of Adjuvant T-DXd vs T-DM1 for High-Risk HER2+ EBC With Residual Invasive Disease After Neoadjuvant Therapy

Conference Coverage
Slideset

In patients with high-risk HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy, adjuvant T-DXd demonstrated significant and clinically meaningful improvements in survival outcomes vs T-DM1 in an interim analysis of the phase III DESTINY-Breast05 trial.

Released: October 23, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Incyte, and Lilly.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Incyte

Lilly